Emricasan is an investigational, oral and pan-caspase inhibitor intended to treat NASH with advanced fibrosis (scarring) and cirrhosis. It has been evaluated in around 650 patients in 16 clinical
Under the deal terms, Boston-based Pieris will receive $57.5m of upfront and near-term milestone payments from AstraZeneca. Pieris will advance its lead candidate, PRS-060, an anticalin against interleukin-4 receptor alpha
It failed to demonstrate a statistically significant increase in the median period of overall survival of patients treated with Zoptrex as compared to patients treated with doxorubicin. Zoptarelin doxorubicin is
Rydapt is indicated for use in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy to treat adult patients with newly diagnosed AML who are FLT3 mutation-positive, as
The AZD9412 is a novel inhaled interferon beta therapy, which is being developed to support the immune system by correcting a deficiency that makes vulnerable to respiratory tract
Natpar is claimed to be the first recombinant human protein with the full length 84-amino acid sequence of endogenous parathyroid hormone (PTH), as well as approved hormone therapy
The companies have signed an agreement in December 2016 to jointly develop and commercialize the drug, called vadadustat. The deal called for Akebia to receive $265m in committed funds,
Tagrisso 40mg and 80mg once-daily oral tablet were approved in around 45 countries, including the US, EU, Japan and China, to treat patients with EGFR T790M mutation-positive advanced
Under the deal, Fresenius Kabi will pay $34.00 per Akorn share, in addition to assuming around $450m of debt. Akorn is engaged in the development, manufacturing and marketing
The marketing authorization of the gene therapy was approved in 2012 for the treatment of patients with familial lipoprotein lipase deficiency (LPLD). According to the Dutch gene therapy
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.